Eli Lilly's Foundayo tops 20,000 patients in first weeks
Updated
Updated · CNBC · Apr 30
Eli Lilly's Foundayo tops 20,000 patients in first weeks
12 articles · Updated · CNBC · Apr 30
CEO Dave Ricks said more than 1,000 people a day are starting the once-daily pill, and over 80% are new to GLP-1 treatments.
The FDA approved Foundayo earlier this month, making it the second oral GLP-1 drug after Novo Nordisk's Wegovy pill, as investors watch prescriptions for signs of launch momentum.
Foundayo was not included in first-quarter results, but Lilly said Mounjaro and Zepbound sales rose 125% and 80%, helping it hold a 60.1% US obesity and diabetes drug market share.
Lilly's profits are soaring, but its new pill is struggling. Is its $21B acquisition spree a smart pivot or a panicked diversification?
With Lilly's new pill lagging, what will truly decide who wins the billion-dollar battle for oral weight-loss drugs?
Effective weight-loss drugs exist, yet access is limited. What is the real barrier to solving the obesity crisis?